Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuhui Hu

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Clinical and Translational Science|December 19, 2024
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: A randomized phase I studyNanyang Li, Nannan Chu, Leilei Zhu, et al.
Medicine|May 6, 2016
CEA Level, Radical Surgery, CD56 and CgA Expression Are Prognostic Factors for Patients With Locoregional Gastrin-Independent GNETYuan Li, Xinyu Bi, Jianjun Zhao, et al.
Bioengineering (Basel, Switzerland)|March 28, 2025
HANDSON Hand: Strategies and Approaches for Competitive Success at CYBATHLON 2024Xuhui Hu, Fengkai Guo, Zhikai Wei, et al.
Oncotarget|December 29, 2016
Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastasesJingfei Guo, Qian Zhang, Xinyu Bi, et al.
Cancer Communications (London, England)|October 24, 2024
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 studyYun Liu, Yanfeng Wang, Yanrong Zhu, et al.
Lancet (London, England)|June 1, 2026
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 studyLin Shen, Xiaotian Zhang, Ke Ji, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Clinical and Translational Science|December 19, 2024
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: A randomized phase I studyNanyang Li, Nannan Chu, Leilei Zhu, et al.
Medicine|May 6, 2016
CEA Level, Radical Surgery, CD56 and CgA Expression Are Prognostic Factors for Patients With Locoregional Gastrin-Independent GNETYuan Li, Xinyu Bi, Jianjun Zhao, et al.
Bioengineering (Basel, Switzerland)|March 28, 2025
HANDSON Hand: Strategies and Approaches for Competitive Success at CYBATHLON 2024Xuhui Hu, Fengkai Guo, Zhikai Wei, et al.
Oncotarget|December 29, 2016
Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastasesJingfei Guo, Qian Zhang, Xinyu Bi, et al.
Cancer Communications (London, England)|October 24, 2024
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 studyYun Liu, Yanfeng Wang, Yanrong Zhu, et al.
Lancet (London, England)|June 1, 2026
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 studyLin Shen, Xiaotian Zhang, Ke Ji, et al.
Pageof 4